[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oruka Therapeutics Inc (ORKA)

Oruka Therapeutics Inc (ORKA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics...

ORKA : 73.99 (-3.14%)
Tech Earnings Optimism Powers Stocks Higher

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.01%. June E-mini...

ALK : 39.79 (-1.61%)
UAL : 90.41 (-1.62%)
AMAT : 381.11 (-5.87%)
SNDK : 1,002.35 (-6.34%)
VZ : 47.24 (+0.30%)
ADI : 383.26 (-2.38%)
TXN : 265.00 (-1.67%)
$IUXX : 27,029.01 (-1.01%)
ELV : 362.74 (+1.86%)
UNH : 366.77 (+3.41%)
ASML : 1,384.56 (-3.34%)
DPZ : 340.46 (+1.54%)
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics...

ORKA : 73.99 (-3.14%)
Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. June E-mini S&P futures...

ALK : 39.79 (-1.61%)
UAL : 90.41 (-1.62%)
AMAT : 381.11 (-5.87%)
SNDK : 1,002.35 (-6.34%)
VZ : 47.24 (+0.30%)
ADI : 383.26 (-2.38%)
TXN : 265.00 (-1.67%)
$IUXX : 27,029.01 (-1.01%)
DPZ : 340.46 (+1.54%)
ZNM26 : 110-295 (+0.06%)
ESM26 : 7,178.50 (+0.10%)
NCLH : 17.79 (-2.20%)
Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX ) (SPY ) today is unchanged, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. June E-mini S&P futures (ESM26...

AAPL : 270.71 (+1.16%)
CRWD : 454.99 (+0.08%)
VZ : 47.24 (+0.30%)
$SPX : 7,138.80 (-0.49%)
MU : 504.29 (-3.86%)
MANE : 103.10 (+3.00%)
$IUXX : 27,029.01 (-1.01%)
NQM26 : 27,242.00 (+0.27%)
DPZ : 340.46 (+1.54%)
QQQ : 657.55 (-1.01%)
CLM26 : 99.40 (-0.53%)
ZNM26 : 110-295 (+0.06%)
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing,...

ORKA : 73.99 (-3.14%)
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 73.99 (-3.14%)
Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run?

Oruka Therapeutics (ORKA) has strong technical momentum and is trading at a new 5-year high. Shares are up nearly 840% over the past year. ORKA maintains a 100% “Buy” technical opinion from Barchart....

ORKA : 73.99 (-3.14%)
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated...

ORKA : 73.99 (-3.14%)
Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 73.99 (-3.14%)

Barchart Exclusives

Warren Buffett’s Berkshire Hathaway Is Losing Money in This Dividend Stock: Can It Work for You?
Domino's Pizza has a dividend yield of 2.4%, and its dividends have risen at an annualized pace of nearly 20% over the last 10 years. Does that make the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.